company background image
SHE

Shedir Pharma Group BIT:SHE Stock Report

Last Price

€2.80

Market Cap

€32.0m

7D

-6.7%

1Y

-32.2%

Updated

02 Jul, 2022

Data

Company Financials +
SHE fundamental analysis
Snowflake Score
Valuation4/6
Future Growth1/6
Past Performance1/6
Financial Health5/6
Dividends3/6

SHE Stock Overview

Shedir Pharma Group S.p.A., through its subsidiaries, engages in the nutraceutical and pharmaceutical business in Italy.

Shedir Pharma Group Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Shedir Pharma Group
Historical stock prices
Current Share Price€2.80
52 Week High€5.22
52 Week Low€2.80
Beta0.79
1 Month Change-21.13%
3 Month Change-31.87%
1 Year Change-32.20%
3 Year Changen/a
5 Year Changen/a
Change since IPO-59.76%

Recent News & Updates

Oct 05
Why Shedir Pharma Group's (BIT:SHE) Earnings Are Better Than They Seem

Why Shedir Pharma Group's (BIT:SHE) Earnings Are Better Than They Seem

Shedir Pharma Group S.p.A.'s ( BIT:SHE ) solid earnings announcement recently didn't do much to the stock price. We did...

Shareholder Returns

SHEIT PharmaceuticalsIT Market
7D-6.7%-0.01%-2.7%
1Y-32.2%8.9%-17.1%

Return vs Industry: SHE underperformed the Italian Pharmaceuticals industry which returned 8.9% over the past year.

Return vs Market: SHE underperformed the Italian Market which returned -17.1% over the past year.

Price Volatility

Is SHE's price volatile compared to industry and market?
SHE volatility
SHE Average Weekly Movement4.6%
Pharmaceuticals Industry Average Movement5.6%
Market Average Movement5.1%
10% most volatile stocks in IT Market7.3%
10% least volatile stocks in IT Market3.3%

Stable Share Price: SHE is not significantly more volatile than the rest of Italian stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: SHE's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
200871Antonio Scalahttps://www.shedirpharma.com

Shedir Pharma Group S.p.A., through its subsidiaries, engages in the nutraceutical and pharmaceutical business in Italy. The company offers supplements, medical devices, dermo-cosmetics, and drugs. It also provides products for andrological, cardiovascular, dermatological, hematological, energy, gastrointestinal, gynecological, metabolic, neurological, dental, ophthalmic, osteoarticular, ontological, respiratory, and trichological diseases.

Shedir Pharma Group Fundamentals Summary

How do Shedir Pharma Group's earnings and revenue compare to its market cap?
SHE fundamental statistics
Market Cap€32.00m
Earnings (TTM)€3.93m
Revenue (TTM)€44.82m

8.2x

P/E Ratio

0.7x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
SHE income statement (TTM)
Revenue€44.82m
Cost of Revenue€30.88m
Gross Profit€13.95m
Other Expenses€10.02m
Earnings€3.93m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)0.34
Gross Margin31.12%
Net Profit Margin8.76%
Debt/Equity Ratio28.3%

How did SHE perform over the long term?

See historical performance and comparison

Dividends

4.6%

Current Dividend Yield

38%

Payout Ratio
We’ve recently updated our valuation analysis.

Valuation

Is SHE undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for SHE?

Other financial metrics that can be useful for relative valuation.

SHE key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue0.6x
Enterprise Value/EBITDA3.5x
PEG Ration/a

Price to Earnings Ratio vs Peers

How does SHE's PE Ratio compare to its peers?

SHE PE Ratio vs Peers
The above table shows the PE ratio for SHE vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average31.2x
PRL Pierrel
18.1x36.8%€46.0m
FCM Friulchem
72.1x52.1%€6.1m
REC Recordati Industria Chimica e Farmaceutica
22.5x8.9%€8.8b
ABS Arterra Bioscience
12.2xn/a€13.5m
SHE Shedir Pharma Group
8.2xn/a€32.0m

Price-To-Earnings vs Peers: SHE is good value based on its Price-To-Earnings Ratio (8.2x) compared to the peer average (31.2x).


Price to Earnings Ratio vs Industry

How does SHE's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?

Price-To-Earnings vs Industry: SHE is good value based on its Price-To-Earnings Ratio (8.2x) compared to the European Pharmaceuticals industry average (18.4x)


Price to Earnings Ratio vs Fair Ratio

What is SHE's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SHE PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio8.2x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate SHE's Price-To-Earnings Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of SHE when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: SHE (€2.8) is trading below our estimate of fair value (€23.73)

Significantly Below Fair Value: SHE is trading below fair value by more than 20%.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate SHE's PEG Ratio to determine if it is good value.


Discover undervalued companies

Future Growth

How is Shedir Pharma Group forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

Future Growth Score

1/6

Future Growth Score 1/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


9.3%

Forecasted annual revenue growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if SHE's forecast earnings growth is above the savings rate (1.7%).

Earnings vs Market: Insufficient data to determine if SHE's earnings are forecast to grow faster than the Italian market

High Growth Earnings: Insufficient data to determine if SHE's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: SHE's revenue (9.3% per year) is forecast to grow faster than the Italian market (0.3% per year).

High Growth Revenue: SHE's revenue (9.3% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: SHE's Return on Equity is forecast to be low in 3 years time (16.6%).


Discover growth companies

Past Performance

How has Shedir Pharma Group performed over the past 5 years?

Past Performance Score

1/6

Past Performance Score 1/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-9.4%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: SHE has high quality earnings.

Growing Profit Margin: SHE's current net profit margins (8.8%) are lower than last year (9.1%).


Past Earnings Growth Analysis

Earnings Trend: SHE's earnings have declined by 9.4% per year over the past 5 years.

Accelerating Growth: SHE's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: SHE had negative earnings growth (-0.03%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (17.7%).


Return on Equity

High ROE: SHE's Return on Equity (14%) is considered low.


Discover strong past performing companies

Financial Health

How is Shedir Pharma Group's financial position?

Financial Health Score

5/6

Financial Health Score 5/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: SHE's short term assets (€40.7M) exceed its short term liabilities (€14.4M).

Long Term Liabilities: SHE's short term assets (€40.7M) exceed its long term liabilities (€10.0M).


Debt to Equity History and Analysis

Debt Level: SHE has more cash than its total debt.

Reducing Debt: Insufficient data to determine if SHE's debt to equity ratio has reduced over the past 5 years.

Debt Coverage: SHE's debt is well covered by operating cash flow (148.4%).

Interest Coverage: SHE's interest payments on its debt are well covered by EBIT (26.9x coverage).


Balance Sheet


Discover healthy companies

Dividend

What is Shedir Pharma Group current dividend yield, its reliability and sustainability?

Dividend Score

3/6

Dividend Score 3/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage


4.64%

Current Dividend Yield

Dividend Yield vs Market

Notable Dividend: SHE's dividend (4.64%) is higher than the bottom 25% of dividend payers in the Italian market (1.73%).

High Dividend: SHE's dividend (4.64%) is low compared to the top 25% of dividend payers in the Italian market (5.16%).


Stability and Growth of Payments

Stable Dividend: Too early to tell whether SHE's dividend payments have been stable as they only just started paying a dividend.

Growing Dividend: Too early to tell if SHE's dividend payments are increasing as they only just started paying a dividend.


Earnings Payout to Shareholders

Earnings Coverage: With its reasonably low payout ratio (37.9%), SHE's dividend payments are well covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: With its low cash payout ratio (15.4%), SHE's dividend payments are well covered by cash flows.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

3.5yrs

Average board tenure


CEO

Antonio Scala (38 yo)

3.5yrs

Tenure

Mr. Antonio Scala serves as Managing Director and Chief Executive Officer of Shedir Pharma Group S.P.A. since 2019 and serves as its Director. Mr. Scala graduated in International Economics at the Universi...


Board Members

Experienced Board: SHE's board of directors are considered experienced (3.5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Shedir Pharma Group S.p.A.'s employee growth, exchange listings and data sources


Key Information

  • Name: Shedir Pharma Group S.p.A.
  • Ticker: SHE
  • Exchange: BIT
  • Founded: 2008
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: €32.004m
  • Shares outstanding: 11.43m
  • Website: https://www.shedirpharma.com

Number of Employees


Location

  • Shedir Pharma Group S.p.A.
  • Via Bagnulo 95
  • Piano di Sorrento
  • Napoli
  • Naples
  • 80063
  • Italy

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/07/02 00:00
End of Day Share Price2022/07/01 00:00
Earnings2021/12/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.